Replies to post #379 on Precigen Inc. (PGEN)

[jondoeuk]

Thanks. I had issues with the target for PGEN-3006, as back during an ISCT '17 presentation, Dr. Saar Gill suggested that just hitting CD123, or CD33 in AML was a non-starter, and smarter approach needed. Based on that and the comments from the PI, I think the company should discontinue the program.